CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
82.41
-0.54 (-0.65%)
At close: 4:00PM EDT

82.70 +0.29 (0.35%)
Pre-Market: 7:07AM EDT

Stock chart is not supported by your current browser
Previous Close82.95
Open83.00
Bid82.70 x 1200
Ask83.00 x 900
Day's Range82.20 - 84.17
52 Week Range74.13 - 123.25
Volume2,705,287
Avg. Volume4,614,876
Market Cap57.964B
Beta (3Y Monthly)1.33
PE Ratio (TTM)22.92
EPS (TTM)3.60
Earnings DateOct 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.65
Trade prices are not sourced from all markets
  • Business Wire21 minutes ago

    First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

    IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy combination in first-line metastatic triple negative breas

  • See what the IHS Markit Score report has to say about Celgene Corp.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELG

  • The Wall Street Journal3 days ago

    [$$] Pain Treatment Developer Centrexion Reveals IPO Plans

    Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public.

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist3 days ago

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Investopedia3 days ago

    Biotech Sector Could Enter Bear Market

    Biotech price action at all capitalization levels has deteriorated in recent weeks, with the two major sector funds giving up the majority of their 2018 gains. The iShares Nasdaq Biotechnology Index Fund ( IBB) and the SPDR S&P Biotech ETF ( XBI) carve different price patterns due to their unique holdings and construction. The market-cap weighted Nasdaq fund is dependent upon its biggest components, with Amgen Inc. ( AMGN), Gilead Sciences, Inc. ( GILD), Biogen Inc. ( BGEN) and Celgene Corporation ( CELG) comprising more than 32% of portfolio weighting.

  • Agios Rides on Tibsovo Approval Amid Reliance on Celgene
    Zacks3 days ago

    Agios Rides on Tibsovo Approval Amid Reliance on Celgene

    Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.

  • Analyzing Biogen before Its Third-Quarter Earnings
    Market Realist3 days ago

    Analyzing Biogen before Its Third-Quarter Earnings

    Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.

  • Investors Hunt for Biotech Winners as Wider Stock Market Churns
    Bloomberg3 days ago

    Investors Hunt for Biotech Winners as Wider Stock Market Churns

    Since hitting a 52-week high on Oct. 1, the Nasdaq Biotechnology Index, the broadest gauge of the industry’s performance, has fallen more than 6.5 percent. On top of the economic and political anxieties pushing the market lower, many large biotech companies had already been dragged down by the Trump administration’s campaign to lower drug prices, as well as fears that companies like Celgene Corp. and Gilead Sciences Inc. lack clear successors for older blockbusters that will face cheaper competitors in coming years. Celgene and other large biotechs like Biogen Inc. and Vertex Pharmaceuticals Inc. have led the Nasdaq index lower in recent weeks.

  • Pfizer’s Growth Rate and Estimates
    Market Realist4 days ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • 5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage
    InvestorPlace5 days ago

    5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage

    For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.

  • CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
    Zacks5 days ago

    CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks6 days ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • Celgene (CELG) Dips More Than Broader Markets: What You Should Know
    Zacks7 days ago

    Celgene (CELG) Dips More Than Broader Markets: What You Should Know

    Celgene (CELG) closed at $81.83 in the latest trading session, marking a -0.91% move from the prior day.

  • 5 Stocks to Absolutely Love During This Correction
    Motley Fool10 days ago

    5 Stocks to Absolutely Love During This Correction

    The stock market is dropping, which means it could be time to go shopping.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool11 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Analyzing Celgene’s Immunology and Inflammation Business
    Market Realist11 days ago

    Analyzing Celgene’s Immunology and Inflammation Business

    How's Celgene Positioned before Its Third-Quarter Earnings? Otezla’s net revenues grew from $358.0 million in the second quarter of 2017 to $375.0 million in the second quarter, which reflects ~4.7% growth YoY (year-over-year). In the US market, Otezla fell 4.9% YoY in the second quarter and reported revenues of $291.0 million.

  • Business Wire11 days ago

    Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy

    A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. The survey, conducted by the Multiple Sclerosis Association of America (MSAA) and sponsored by Celgene, included more than 1,300 people with multiple sclerosis or someone responding on their behalf.

  • Investopedia12 days ago

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist12 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
    Zacks12 days ago

    Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status

    Data presentations by leading sector players take center stage this week.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist12 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • Reuters12 days ago

    BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China

    Oct 10 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES NATIONAL REIMBURSEMENT INCLUSION OF VIDAZA® (AZACITIDINE FOR INJECTION) BY THE STATE MEDICAL INSURANCE ADMINISTRATION IN CHINA * BEIGENE SAYS VIDAZA ...

  • Business Wire12 days ago

    New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

    Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial

  • The Wall Street Journal12 days ago

    [$$] The Menendez Method

    After narrowly dodging a corruption conviction, New Jersey Senator Bob Menendez faces a re-election dogfight against former Celgene CEO Bob Hugin. The Senator is now lying to voters about his opponent’s business record the way he dissembled about his political corruption. Democrats always treat a Republican candidate from business as if commerce is by definition criminal, and Mr. Hugin is no exception.

  • Better Buy: Crispr Therapeutics AG vs. Editas
    Motley Fool13 days ago

    Better Buy: Crispr Therapeutics AG vs. Editas

    Which gene editing start-up has the best chance to outperform in the years ahead?